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ABSTRACT
Despite decades of research, and the growing
healthcare and societal burden of chronic obstructive
pulmonary disease (COPD), therapeutic COPD break-
throughs have not occurred. Sub-optimal COPD
patient phenotyping, an incomplete understanding of
COPD pathogenesis and a scarcity of sensitive tools
that provide patient-relevant intermediate endpoints
likely all play a role in the lack of new,efficacious COPD
interventions. In other words, COPD patients are still
diagnosed based on the presence of persistent airflow
limitation measured using spirometry. Spirometry
measurements reflect the global sumof all the different
possible COPD pathologies and perhaps because of
this, we lose sight of the different contributions of
airway and parenchymal abnormalities. With recent
advances in thoracic X-ray computed tomography (CT)
andmagnetic resonance imaging (MRI), lung structure
and function abnormalities may be regionally identi-
fied andmeasured.These imaging endpointsmay serve
as biomarkers of COPD that can be used to better phe-
notype patients. Therefore, here we review novel CT
and MRI measurements that help reveal COPD pheno-
types and what COPD really ‘looks’ like, beyond
spirometric indices. We discuss MR and CT imaging
approaches for generating reproducible and sensitive
measurements of COPD phenotypes related to pulmo-
nary ventilation and perfusion as well as airway and
parenchyma anatomical and morphological features.
Thesemeasurementsmayprovide away to advance the
development and testing of new COPD interventions
and therapies.
Keywords: chronic obstructive pulmonary disease, computed
tomography, imaging, phenotype, magnetic resonance imaging.
Abbreviations: 3D, three-dimensional; 4DCT, four-
dimensional CT; ACOS, asthma-COPD overlap syndrome; ADC,
apparent diffusion coefficient; COPD, chronic obstructive pulmo-
nary disease; CT, computed tomography; FDMRI, Fourier-
decomposition MRI; FEV1, forced expiratory volume in 1 s; FGRE,
fast recalled gradient echo; FVC, forced vital capacity; HU,
Hounsfield Unit; LAC, low attenuation cluster; MRI, magnetic
resonance imaging; OE-MRI, oxygen-enhanced MRI; PET, posi-
tron emission tomography; PRM, parametric response maps; RA,
relative area; RV, and the residual volume; SPECT, single photon
emission computed tomography; TLC, total lung capacity; UTE,
ultra-short echo time.
INTRODUCTION
What does chronic obstructive pulmonary disease
(COPD) really look like? For years, even though our
understanding of COPD has been based on global
measurements of lung function, it was well-
understood that disease features and phenotypes
could be gleaned by ‘looking’ at the patient. However,
in spite of this, and the fact that COPD is recognized
as a heterogeneous disease with different contribu-
tions from airway1 and parenchymal abnormalities,2
the diagnosis and monitoring of patients and their
response to therapy are currently made using airflow
measurements. These measurements, while impor-
tant, may conceal the independent contributions of
underlying COPD pathologies especially in the early
stages of disease.
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According to the World Health Organization, by the
year 2030, COPD will be the third leading cause of
death worldwide.3 Therapies that modify COPD out-
comes are still lacking and perhaps our reliance on
spirometry measurements is partly responsible for
this. While pulmonary function test measurements
provide a straightforward and reproducible/easy to
use way to measure lung function,4 these measure-
ments sometimes disguise or conceal different COPD
phenotypes. Accordingly, one goal of COPD research
is the development of ways to identify COPD patients
with specific underlying pathological phenotypes
with the hope that this will improve on patient care
and outcomes.
In this regard, imaging methods such as chest X-ray,
thoracic computed tomography (CT), single photon
emission computed tomography (SPECT), positron
emission tomography (PET), and magnetic resonance
imaging (MRI) have played a role in the visualization
of pulmonary structure and function in COPD. Quan-
titative imaging (i.e. imaging biomarkers) employed
in research studies (but not yet clinical use), such as
COPDGene,5 ECLIPSE,6 SPIROMICS7 and MESA,8 has
provided repeatable and unbiased estimates of the
severity and distribution of lung pathology. Here, we
review novel imaging biomarkers utilized in large and
small cohort studies that may help unmask the many
‘faces’ of COPD.
X-RAY CT
Using X-ray CT, the characterization of COPD has
evolved beyond the traditional distinctions of
‘emphysema’ and ‘chronic bronchitis’ based on the
presence and type of emphysema (i.e. centrilobular,
panlobular, paraseptal),9,10 the presence of bullae,10
and their location (i.e. upper lung, lower lung,
diffuse),10 small airway disease, air-trapping, bron-
chial wall dilatation, wall thickening, as well as large
airway disease.11 With the introduction of clinical CT
in the 1970s,12 and with the use of computer-based
image-analysis methods (summary of technical terms
and concepts is provided in Table 1), the qualitative
evaluation of underlying lung disease in COPD
patients has matured to the evaluation of quantitative
and objective regional measurements.13
Structural CT
Emphysema phenotypes
The CT image was originally assessed using visual
scoring systems modelled after pathology. These
scoring systems are still in use today, but studies have
shown that they are subject to high inter- and intra-
user variability.14,15 However, the CT image is a
densitometric map, where each voxel corresponds to
a Hounsfield Unit (HU) value that directly reflects the
radiodensity of a material. Consequently, air has a
lower HU value (i.e. lower radiodensity) correspond-
ing to lower signal intensity in a CT image and bone
and tissue have relatively greater HU values because
they are much more radiation absorptive. Figure 1
shows this in the axial and coronal CT images and a
three-dimensional (3D) low attenuation cluster (LAC)
map for an ex-smoker with emphysema-dominant
COPD. The black arrows indicate large regions with
mainly air (1 cm to several centimetres), or emphyse-
matous bullae, primarily in the upper lobes. This
figure also contains images from a subject that
appears to have thickened airway walls and another
subject that exhibits a mixture of airway wall thicken-
ing and emphysema. Quantitative analysis of the CT
density histogram from these images can be done
using computerized and automated methods
whereby the CT density histogram of all Hounsfield
unit values is evaluated using a threshold to generated
the relative area (RA) of the lung occupied by attenu-
ation values less than specific thresholds (e.g.
−950HU (RA950) or percentiles including the 15th per-
centile (HU15)). These measurements of emphysema
correlate well with radiologists’ scores,15 pulmonary
function tests16 and histology.17 However, an impor-
tant limitation is that the threshold appropriate for
emphysema is subject to image acquisition and
reconstruction parameters. Moreover, the use of a
single threshold can over- or under-estimate the pres-
ence of emphysema,18 and may not be sensitive to
regions with mild tissue destruction.19
Although these densitometric analyses (i.e.
threshold-based methods) provide an unbiased
measurement of emphysema severity, they do not
express the regional heterogeneity of disease. One of
the limitations of these methods is that the different
subtypes of emphysema (i.e. centrilobular, paraseptal
and panlobular), although visualized by CT, are con-
cealed by a single number. These subtypes are typi-
cally classified based on visual assessment. Previous
work has demonstrated subtype specific associations
with clinical characteristics that support the notion of
distinct pulmonary phenotypes according to emphy-
sema subtype.20
Image analysis methods based on patterns of local
features provide a way to objectively differentiate
between these subtypes and some of these methods
have better classification rates than expert radiolo-
gists.21 The most straightforward of these approaches
Table 1 List of technical terms and concepts
Term Definition
Echo time Time between MRI excitation and
acquisition
Hounsfield unit Measurement of radiodensity
Hyperpolarization Enhancing polarization beyond thermal
equilibrium conditions
Fourier
transformation
An operation that decomposes a
function into the frequencies
Registration Transforming an image from one
co-ordinate system to another
Segmentation Partitioning an image into different
components
Thresholding Isolating a part of an image based on
the pixel signal intensity
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is cluster analysis, where low attenuation voxels are
identified using a threshold technique and they are
quantified based on how many are connected or
clustered together.22 As shown in Figure 1, the
emphysema-dominant subject has large bullae in the
upper lobes as identified by large clusters of CT low-
attenuation regions and the subject with both emphy-
sema and airways disease has a combination of large
and small clusters distributed throughout the lung.
The so-called low attenuation clusters are visually
obvious, correlating with histopathology measure-
ments23 and more closely reflecting scoring per-
formed by a radiologist.24 Another method for
quantifying emphysema is based on local binary
patterns25 and was shown to have a 95% classifica-
tion accuracy for discriminating panlobular and
centrilobular emphysema. Another approach
involves principal component analysis of the CT
density histogram26 whereby a score based on each
frequency–HU pair26 is derived. While these methods
may offer greater sensitivity than visual inspection,
they can be difficult to integrate into clinical
workflows.
Airways disease phenotypes
Airways disease in COPD patients presents with
varying diagnoses and symptoms including chronic
bronchitis (i.e. chronic cough vs chronic cough and
phlegm) and bronchiectasis (associated with
pathologic airway dilation). As shown in Figure 1, the
CT image allows investigators to obtain images of
airways in cross section, similar to a pathologic image
or, using new techniques, create three dimensional
airway trees that show the branching pattern from the
trachea to the 5th or 6th generation. The yellow
arrows in the axial slice indicate cylindrical bronchi-
ectasis, whereas the arrows in the coronal view show a
signet ring and varicose bronchiectasis. These images
can be used to quantify airway dimensions thus pro-
viding an understanding of bronchial inflammation
and remodelling and allow the stratification of
disease caused by emphysematous lung destruction
from airway remodelling.
Initial studies of CT airway measurements involved
manually tracing the airway using the printed image.
However, this process was very labour-intensive and
susceptible to inter- and intra-observer error.27 Cur-
rently, there are commercially available software
packages that provide a way to reconstruct the
airways from volumetric datasets (Fig. 2, Pulmonary
Workstation V.2.0 VIDA Diagnostics, Coralville, Iowa,
USA). These software tools and others (e.g. Thoracic
VCAR (General Electric Healthcare, Milwaukee, USA),
Apollo Image analysis software (VIDA Diagnostics),
Mimics Innovation Suite (Materialise, Leuven,
Belgium), Pulmo3D Software (Fraunhofer MEVIS,
Bremen, Germany), Airway Inspector (Harvard
Medical School, Boston, MA) and 3D SLICER (http://
www.slicer.org, Boston, MA)) allow for the quantifica-
tion of luminal diameter and wall thickness to the
fifth or sixth airway generation. Indices of airway
dimensions include total bronchial area, bronchial
luminal area, bronchial wall thickness and area and
the per cent of the total bronchial area that is wall area
per cent (WA%).28 Another measure of bronchial
wall area (or thickness) that was developed to try and
Figure 1 Structural thoracic X-ray com-
puted tomography images. Axial and
coronal CT and low attenuation clusters
(LAC) of emphysema, represented as
spheres with CT densitometry values
below −950 HU registered to the three-
dimensional reconstruction of the airway
tree shown below. Yellow arrows indicate
airways disease and black arrows indicate
emphysematous regions. From left to right:
airways disease dominant, emphysema
dominant and mixed phenotype. Airways
disease dominant: FEV1 = 103%pred,
DLCO = 119%pred, RA950 = 1%; Emphysema
dominant: FEV1 = 65%pred, DLCO = 17%pred,
RA950 = 37%; Mixed: FEV1 = 47%pred,
DLCO = 62%pred, RA950 = 15%.
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alleviate the error in the WA% caused by measuring
small airways, is the square root of wall area of an
idealized airway with an internal perimeter of 10 mm
(Pi10),29 which is calculated using a linear regression
of all measured bronchi.
One of the first studies of airway dimensions dem-
onstrated that WA% correlated with the forced
expiratory volume in 1 s (FEV1), forced vital capacity
(FVC), and the residual volume/total lung capacity
(RV/TLC), but not DLCO.30 Since then, studies have
shown that airway wall measurements are associated
with histology,29 frequency of exacerbations31 and
dyspnea.32 Previous studies also examined subjects
with COPD and the clinical diagnosis of chronic
bronchitis and determined that subjects with
chronic bronchitis and COPD had thicker airway
walls than those without chronic bronchitis and
COPD.33 Recent work showed that quantitative CT
measures of airway thickness in COPD patients were
greater in those with bronchodilator responsive-
ness.34 Most of the studies published to date tend to
take all the airway measurements and use them
together as a single global measurement. However, a
recent study suggests that airways need to be
described in terms of their anatomic location35 and
according to number of generations from the
trachea. This approach showed that in some COPD
patients, airway walls become thinner and not
thicker. A previous study also compared airway
measurements in patients with asthma-COPD
overlap syndrome (ACOS) and those with COPD
patients and demonstrated that subjects with ACOS
had significantly higher WA%, but similar emphy-
sema scores.36 To date, these analytical approaches
have not revealed strong correlations between lung
function and CT measurements of emphysema and
airway wall remodelling, and this is very likely
because there are very few, if any, patients with
exclusively one phenotype. Most subjects with mod-
erate disease report a mixture of airway wall abnor-
malities and parenchymal destruction, and it
emphasizes the point that the lung needs to be
Figure 2 Functional thoracic X-ray com-
puted tomography images. Coronal CT,
Hounsfield Unit density plots, parametric
response maps (PRM), and reconstructed
CT airway trees are shown below. From
left to right: airways disease dominant,
emphysema dominant and mixed pheno-
type. Airways disease dominant:
WA = 64%, PRM Normal Tissue = 73%,
PRM Gas Trapping = 26%, PRM Emphy-
sema = 1%; Emphysema dominant:
WA = 63%, PRM Normal Tissue = 42%,
PRM Gas Trapping = 17%, PRM Emphy-
sema = 38%; Mixed: WA = 59%, PRM
Normal Tissue = 28%, PRM Gas Trap-
ping = 47%, PRM Emphysema = 24%.
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assessed regionally and global measurements miss
both functional and anatomic changes.
Finally, it should also be recognized that the use of
CT to quantify and classify emphysema and airways
disease severity can be challenging. For example,
inconsistent scanning and image reconstruction
parameters37 and poor coaching of the patient to the
targeted lung volume38 are some of the image acqui-
sition issues that limit more widespread use.
Functional CT
Pairing regional structural and functional informa-
tion is critical for understanding the aetiology of
COPD. By understanding the emphysema and airway
components without tying these to functional
consequences, we remain blind to the variations in
pulmonary perfusion and ventilation and, more
importantly, the complete picture of COPD. Thus, by
taking into account the functional changes that
accompany structural changes, we will be one step
closer to comprehensive individualized disease char-
acterization.
Gas trapping and ventilation phenotypes
Conventional CT is limited to the evaluation of lung
parenchyma and airway abnormalities. However,
recently, investigators have started to use CT images
acquired at both end inspiration and expiration to try
and assess low attenuation areas due to emphysema-
tous destruction and air-trapping related to small
airway disease.5 Investigators have taken this a step
farther and have co-registered the inspiratory and
expiratory CT images to generate parametric
response maps (PRM), to further describe low attenu-
ation areas on the CT scans as emphysematous or due
to gas trapping because of small airway disease,
termed ‘functional small airway disease’ (Fig. 2). As
shown in the PRM maps provided in Figure 2, the
airways disease dominant COPD subject has regions
of gas trapping in the lower lobes (indicative of small
airways disease) and no obvious regions of emphy-
sema. The subject with emphysema dominant COPD
has obvious bullous regions, and the subject with the
mixed phenotype has contributions from both small
airways disease and emphysema. In comparison to
the anatomical coronal CT slices shown, the PRM
maps allow for the regional quantification of gas trap-
ping and emphysema. These PRM measurements of
gas trapping and emphysema have been shown to be
associated with pulmonary function tests, quality of
life questionnaires and frequency of exacerbations.39
Pulmonary function has also been evaluated using
xenon-enhanced dual-energy CT. Dynamic CT
images are acquired during the wash-in of xenon gas
during inhalation or wash-out of xenon gas during
exhalation. This work showed that there was an
inverse relationship for xenon gas wash-out with lung
function40 and point to the relationship between
trapped gas or slow emptying units and conventional
pulmonary function measurements. Thoracic
imaging functional maps and measurements are pos-
sible using four-dimensional CT (4DCT).41 Originally
developed for radiotherapy treatment planning,
4DCT allows for the acquisition of the 3D image
throughout the respiratory cycle. Although good
agreement between ventilation MRI and 4DCT has
been demonstrated in lung cancer patients,42 because
of radiation dose, 4DCT is not suited for longitudinal
monitoring of COPD. Alternative methods have
emerged for the acquisition of thoracic images at
multiple lung volumes without contrast agents. For
example, a two-lung volume (TLC and RV) CT proto-
col has been standardized as part of the ‘SPIROMICS’7
study. Using this approach in combination with
advanced image registration methods,43 lung ventila-
tion maps may be generated and evaluated.
Perfusion phenotypes
In COPD patients pulmonary abnormalities stem
from inflammatory processes, triggered by inhaled
noxious particles. Remarkably, in about half of
smokers, the inflammatory process is self-repairing;
however, in the remainder, inflammation results in
airway and parenchymal abnormalities.44,45 Impor-
tantly, hypoxic pulmonary vasoconstriction is nor-
mally blocked in the presence of inflammation.46 To
ascertain the influence of inflammation on pulmo-
nary perfusion, dynamic CT methods have been
used to measure blood flow and mean transit time.47,48
This work showed that early or mild emphysema is
characterized by heterogeneous pulmonary perfu-
sion possibly due to inflammation.49 Moreover,
CT-perfusion studies suggested that blood flow is
diminished to inflamed lung regions in patients with
emphysema.
MAGNETIC RESONANCE IMAGING
Although pulmonary MRI remains technically chal-
lenging due to the unique characteristics of lung
tissue, MRI using hyperpolarized noble gases and
conventional methods has helped to change our
understanding of COPD.
Proton MRI phenotypes
MRI of the lung is demanding for several reasons.
First, the lung parenchyma is predominately com-
posed of alveolar ducts and alveoli, which are air-
filled, and thus very little 1H signal that can be
detected from the small amount of tissue present.
Second, the lung parenchyma also has a short
transverse magnetization relaxation time, known as
T2, and consequently a short T2* which is the sum of
the T2 relaxation time and an additional field
inhomogeneity term. This magnetic property of the
lung results in a much faster MR signal decay for the
lung parenchyma in comparison to other tissues.
Third, the air and tissue have very different magnetic
properties and the air–tissue interfaces, such as those
at the alveolar membrane, result in magnetic field
gradients that may further degrade the 1H signal and
distort the image.
Proton MRI anatomical and microstructural
imaging
Although hampered by low signal intensity, pulmo-
nary 1H MRI can be performed on conventional
K Sheikh et al.228
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scanners without a great deal of physics support. For
example, methods have been devised that combine
relaxation signals and intravenous contrast to differ-
entiate inflammation,50 smooth muscle remodelling,
oedema and mucus deposition.50,51 Conventional 1H
MRI allows for the visualization and quantification of
emphysema,52 the differentiation of oedema from
mucous deposition50,51 and the differentiation of
emphysema from mucous plugs53; these findings
point to the potential of 1H MRI to help unmask the
many faces of COPD.
Recent technical advancements using short and
ultra-short echo time (UTE) acquisition methods help
address the inherent challenges of low tissue and 1H
density54 by minimizing the effects of rapid MR signal
decay. Figure 3 shows 1H UTE MR signal intensity
maps of three representative COPD subjects. For
signal intensity maps, cool colours represent regions
of low signal intensity (or diminished tissue density
such as in emphysema) and the warmer colours rep-
resent regions of high signal intensity (or high tissue
density such as in bronchiectasis or airways disease).
The emphysematous and mixed phenotype subjects
have obvious regions of low signal intensity, while in
contrast, the subject with mainly airways disease has
regions with greater signal intensity. The relationship
between MRI signal intensity and tissue density, as
previously shown for pulmonary CT, is clearly impor-
tant for further development of the method. The first
studies employing UTE methods reported that the
tissue density was related to MR signal55 and T2*. More
recently, UTE MRI was implemented to measure
signal intensity and T2* in emphysema56 and showed
good correlations with histological measurements.
UTE MRI in COPD patients also showed that T2* cor-
related with pulmonary function measurements52 and
pulmonary signal intensity was related to tissue
density, pulmonary function and CT density meas-
urements.53 The longitudinal relaxation time (T1) may
be used to characterize COPD patients with emphy-
sema57 because there is a shorter lung T1 in emphyse-
matous tissue than in fibrosis, suggesting that the T1
relaxation time may directly reflect tissue density.
Proton MRI lung function imaging: ventilation
and perfusion
Recently, free-breathing Fourier-decomposition MRI
(FDMRI) was developed as a way to generate regional
ventilation and perfusion maps. Importantly FDMRI
does not require tracer gases because it takes advan-
tage of the very weak but native contrast generated
when air enters and leaves the lung during normal
tidal breathing.58 During a short 2-min scan, both
ventilation (shown in Fig. 3 for three COPD patients)
and perfusion maps can be generated to evaluate
ventilation/perfusion mismatch in COPD patients. As
shown in Figure 3, regions of signal void represent
‘ventilation defects’ that spatially correlated with
inhaled gas MRI ventilation defects and bullae.59
Clearly, the time constants for filling and emptying
the lung may explain the lack of ventilation in some
regions of the lung. Currently, FDMRI utilizes a short-
echo method60 available on most clinical scanners
and can be rapidly performed without exogenous
inhaled gases. This opens up more widespread
Figure 3 1H MR images acquired using
fast recalled gradient echo (FGRE), ultra-
short echo time (UTE) and Fourier Decom-
position MRI of subjects shown below.
From left to right: airways disease domi-
nant, emphysema dominant and mixed
phenotype. Airways disease dominant:
FEV1 = 89%pred, DLCO = 64%pred, RA950 = 2%,
1H UTE signal-intensity = 29%; Emphy-
sema dominant: FEV1 = 28%pred, DLCO =
32%pred, RA950 = 37%, 1H UTE signal-inten-
sity = 22%; Mixed: FEV1 = 52%pred, DLCO =
55%pred, RA950 = 28%, 1H UTE signal-inten-
sity = 22%.
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opportunities for functional lung imaging of COPD
patients on clinical (and not just research) MR
systems.
Oxygen-enhanced MRI phenotypes
Oxygen-enhanced MRI (OE-MRI) takes advantage of
the physical properties of molecular oxygen resident
in the lung. When dissolved in blood, molecular
oxygen shortens the T1-relaxation time of the pulmo-
nary venous blood, and this translates to an increase
in MR signal61 that is dependent upon the presence of
O2 itself. To acquire such images, subjects first breathe
in room air (21% oxygen) for imaging, then 100%
oxygen for a short period of time and then room air
again to generate difference maps. In this manner,
O2-enhanced maps may be generated as per cent
change maps from the oxygen-enhanced and room
air images.62 In a comparison of smokers with and
without COPD, OE-MRI measurements were corre-
lated with smoking history, lung function and CT
measurements. Significant relationships between dif-
fusing capacity for carbon monoxide and signal
intensity derived from OE-MRI were also shown.63
Taken together, this work suggests that OE-MRI has
potential for evaluating pulmonary function in COPD
patients.
Inhaled gas contrast MRI phenotypes
Ventilation phenotypes
Currently, hyperpolarized noble gas MRI using
inhaled 3He and 129Xe gas provides the most common
way to visualize and quantify ventilation (Fig. 4).19
19F MRI has also recently emerged as a ventilation
imaging alternative to hyperpolarized gas MRI64 with
the advantage that perfluorinated gases do not
require any extra polarization.65 Using any of these
ventilated MRI methods, and as shown in Figure 4,
regions of the lung that are not ventilated during
inhalation are revealed as a signal void.66 MRI ventila-
tion imaging also revealed significant bronchodilator
responses in COPD patients (similar in asthma67), not
reflected by FEV1. Figure 5 shows two representative
COPD subjects with and without an imaging bron-
chodilator response. The ventilation defects are visu-
ally reduced post-salbutamol in one COPD subject
similar to what is shown in the asthmatic subject. The
functional information obtained using MRI may help
us understand the clinical differences between ACOS
and COPD and help guide therapy. Ventilation defects
are also a unique predictor of exacerbations68 in
patients with mild disease in whom FEV1 and previ-
ous exacerbations was not prognostic. As shown in
Figure 4, the distribution of ventilation defects varies
for patients with airways-disease dominant, emphy-
sema dominant or mixed airways disease and emphy-
sematous disease.69
Parenchyma phenotypes
In addition to the visualization of gas distribution,
there is also the potential to measure parenchyma
integrity. To enable this, methods have been devel-
oped that are sensitive to 3He gas Brownian motion.
The 3He apparent diffusion coefficient (ADC) reflects
Figure 4 Hyperpolarized noble gas MR
images. 3He and 129Xe static ventilation
and 3He ADC images shown below. From
left to right: airways disease dominant,
emphysema dominant and mixed pheno-
type. Airways disease dominant:
VDP = 8%, ADC = 0.32 cm2/s; Emphysema
dominant: VDP = 12%, ADC = 0.40 cm2/s;
Mixed: VDP = 45%, ADC = 0.42 cm2/s.
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the distance that a He molecule can move within the
airspaces of the lung. These measurements showed
that ex-smokers with and without COPD report sig-
nificantly elevated 3He ADC values compared to
healthy volunteers, reflecting larger airspaces related
to emphysema. The ADC value is attractive because it
correlates with histological measurements of airspace
size70 and is more sensitive than stereology measure-
ments to regional emphysema. ADC values have also
been correlated with pulmonary function test meas-
urements,71 age72 and smoking history.72 Studies in
asymptomatic smokers73 and ex-smokers without
COPD74 have elevated ADC measurements, suggest-
ing that the ADC is a sensitive measure of lung tissue
destruction not obvious using CT73 or reflected by
self-reported symptoms.
Hyperpolarized 129Xe MRI in healthy volunteers
and COPD patients has been reported75,76 but
more importantly 129Xe MRI has the capacity to gen-
erate perfusion images because of the solubility of
129Xe in tissues and blood. This was exploited using
radioactive Xe and allowed physiologists to describe
ventilation and perfusion patterns in the lung.77
Another very important feature of 129Xe is that MR
frequency of Xe shifts as the molecule moves from
the airspace to tissue and blood. This provides a way
to track the kinetic profile of Xe atoms from the gas
phase across the alveolar membrane and into
blood.78
Inhaled gas MRI has also been exploited to esti-
mate the geometry within the alveolar space itself.79
This approach, first pioneered using 3He,79–81 and
then implemented using 129Xe,82 can be used to esti-
mate alveolar length, external airway radii, internal
airway radii and alveolar sheath size. In a similar
fashion, inert 19F ADC in rats83 and excised healthy
Figure 5 Hyperpolarized 3He ventilation
maps pre- and post-salbutamol for a rep-
resentative asthmatic subject (32 year old
female, pre-FEV1 = 33%pred and post-
FEV1 = 50%pred), and COPD subjects with
(73-year-old female, pre-FEV1 = 61%pred
and post-FEV1 = 75%pred) and without (74-
year-old female, pre-FEV1 = 50%pred and
post-FEV1 = 51%pred) imaging bronchodi-
lator response.
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and emphysematous human lungs,84 revealed an
abnormally increased ADC (tissue destruction) in
emphysematous tissue. The use of these novel tools
may prove very useful in α-one antitrypsin defi-
ciency, especially in relation to replacement
therapy.85
MRI AND CT COPD PHENOTYPES:
CHALLENGE OR OPPORTUNITY?
In its current state, CT imaging provides anatomic
imaging with acceptable spatial resolution and image
quality. However, CT also includes a radiation burden
that may be unacceptable in many circumstances
(e.g. longitudinal monitoring). On the other hand,
MRI provides both anatomical and functional images,
without radiation burden, albeit with lower spatial
resolution and in some cases, very poor image quality,
compared to CT. For these reasons, the road towards a
more complete understanding of COPD might
include the complementary information provided by
both methods. For example, as shown in Figures 6 and
7, both CT and MRI can be used in the research setting
to deeply phenotype COPD patients based on quan-
titative lung structure and function. Figure 6 shows
co-registered MRI and CT pulmonary data in a COPD
patient who underwent both imaging methods within
about 30 min, post-salbutamol. The spatial relation-
ship between ventilation defects (MRI) and the airway
tree (CT) of an airways disease-dominant COPD
subject is shown in the axial, sagittal and coronal
plane. Three-dimensional ventilation in transparent
aqua is shown along with the airway tree to identify
the direct airway tree-to-ventilation (structure–
function) spatial relationships, which might prove
important in specific interventions. As shown in the
video, (https://youtu.be/7BFvssgt4zI) the large venti-
lation defect in the lower left lobe and corresponding
airway and emphysema may be clearly identified for
localized or targeted endobronchial interventions.
However, it is also clear that this COPD ex-smoker has
numerous ventilation abnormalities distributed in
the right lung in addition to the larger left lower
lobe abnormality. Furthermore, imaging provides
a way to monitor and compare treatment responses
in patients that have undergone bronchial therm-
oplasty, stent or valve placement. For example, a pre-
vious case study using 3He MRI demonstrated the
benefits of stent therapy in COPD.86 However, further
work is required to validate these observations in
larger studies and to compare stents with other
endobroncial interventions. Using this information,
different COPD phenotypes may be identified that
can potentially benefit from different endobronchial
interventions.
Figure 7 provides an example of another ex-smoker
with emphysema-dominant COPD and the direct
spatial relationship between ventilation abnormal-
ities and an emphysematous bulla (also shown in
video https://youtu.be/T3IGV-9rAEY). This 3D view
suggests that the airways leading to the ventilation
Figure 6 3He MRI ventilation defects and CT represent an emphysema dominant phenotype in chronic obstructive pulmonary disease.
Three-dimensional co-registration of 3He static ventilation (shown in blue) and CT density mask (RA950 map shown in yellow) highlights
the emphysematous regions and airway tree segmented in brown.
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defect are occluded and/or emphysema may be
responsible for the ventilation defect because of long
time-constants for lung filling in the bulla. In com-
parison to the ventilation defect shown in Figure 6,
ventilation defects in Figure 7 are more homogene-
ously distributed, reflecting the fact that each COPD
patient reflects a wide variety of airway, emphysema
and ventilation patterns. We think these different
‘looks’ can be exploited in intervention trials and for
individualized therapy decisions.
SUMMARY AND CONCLUSIONS
The use of CT and MRI in COPD research studies has
evolved over last decades and68,74 has provided new
insights of the pathophysiology of COPD based on a
visual and quantitative picture of the disease. Among
its many strengths, CT is nearly universally available,
images are rapidly acquired and because of the fun-
damental physics of X-ray-based methods, CT pro-
vides high spatial resolution measurements of lung
structure that cannot be achieved using other func-
tional imaging methods. However, for younger
patients, even with low dose adaptive iteration
methods, radiation dose and long-term burden/risk
will always remain a concern for healthcare providers
and for the patients themselves. MRI also provides
quantitative measurements and novel insights about
COPD lung structure and function without exposure
to ionizing radiation, so it provides an excellent alter-
native when dose is a concern. While good agreement
between MRI and CT measurements has been dem-
onstrated, it is clear that MRI and CT methods provide
different information that is very complementary.
Pulmonary function testing is widely accessible,
easy to implement, and offers straightforward meas-
urements that are validated for COPD disease pro-
gression and severity, but they do not tell the whole
story for patient populations and individual patients.
With the advancement of pulmonary imaging
methods, there is growing evidence that different
COPD patients with very similar pulmonary function
measurements, experience the disease differently—
greater or lesser symptoms and exercise capacities. As
therapies begin to become more individualized,
imaging may be the only way to quantify treatment
response. Moreover, imaging may be the only way for
us to see what COPD really looks like.
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